CHColin S. Hill

Colin S. Hill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Colin S. Hill has a total of 108 co-authors. Here are the top co-authors by number of shared publications:

  • Joseph Herman

    Department of Radiation Oncology, Northwell Health Cancer Institute, New Hyde Park, NY 11042, USA

    6 shared publications
  • Amol Narang

    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21287, USA

    5 shared publications
  • Lei Zheng

    Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

    5 shared publications
  • Amol K. Narang

    Department of Radiation Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Cancer Convergence Institute and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland

    4 shared publications
  • Jeffrey Meyer

    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    4 shared publications
  • Jin He

    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    4 shared publications

Latest Publications

  • Open Access

    Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Early-Onset Pancreatic Cancer: Clinical Outcomes and Toxicity

    by Shuchi Sehgal, Abhinav V. Reddy, Suqi Ke, Colin S. Hill, Timothy A. Lin, Serena Mao, Lei Zheng, Jin He, Joseph M. Herman, Chen Hu, et al.

    Purpose/Objective: This purpose of this study is to report on a cohort of patients with Early-onset pancreatic cancer (EOPC) (age < 55 years) who were treated with neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) with or without surgical resection. Materials/Methods: This was a single-institution, retrospective review of patients with EOPC that was staged as either borderline resectable (BRPC) or locally advanced (LAPC) based on NCCN criteria and who were treated with upfront chemotherapy followed by SBRT, with or without subsequent surgical resection. Endpoints included overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and treatment-related toxicity. Results: From 2016 to 2021, 47 patients met the inclusion criteria. The median age was 50.4 years (range, 36.4–54.7 years). The median duration of induction chemotherapy was 4 months (range, 2.5–9.0 months). The SBRT dose for the majority (46/47, 97.9%) of patients was 33 Gy in five fractions. Surgical resection was performed in 33 patients (70.2%). The median OS, LPFS, DMFS, and PFS were 14.2 months, 11.6 months, 8.9 months, and 8.1 months respectively. Six-month and 1-year LPFS were 88.3% and 45.4%, respectively. Chemotherapy duration (≥4 months) was associated with improved median OS (16.5 vs. 10.1 months, p = 0.005), LPFS (10.1 vs. 4.9 months, p = 0.002), DMFS (9.7 vs. 5.2 months, p = 0.014), and PFS (9.7 vs. 5.2 months, p = 0.020). The normalization of CA 19-9 (≤34 vs. >34 U/mL) after chemotherapy was associated with improved median DMFS (not reached vs. 5.6 months, p = 0.003) and PFS (11.3 vs. 5.6 months, p = 0.022). Grade 3+ rates of chemotherapy and radiation-related toxicity were 14.9% and 2.1% respectively. The Clavien–Dindo 3b toxicity rate was 3.0%. Conclusions: In EOPC, an induction chemotherapy duration ≥4 months and the normalization of CA 19-9 after chemotherapy were associated with improved outcomes, suggesting a role for extended durations of systemic therapy titrated to CA 19-9 response before transitioning to local therapy. The high rate of local failure and the low rate of grade 3+ toxicity also suggest a role for intensifying local therapy in this population.

  • Open Access

    Abscopal Effect with Liver-Directed Therapy: A Review of the Current Literature and Future Directions

    by Jonah M. Levine, Alyssar Habib, Mikhail Silk, Greg D. Sacks, Rafael Winograd, Colin S. Hill, Ammar A. Javed, Christopher L. Wolfgang, D. Brock Hewitt

    The liver is a common site for metastatic disease. In select patients with isolated liver metastases, surgical resection improves survival and may be potentially curative in patients with favorable “tumor biology”. However, when surgical resection is not feasible, liver-directed therapies (LDTs) can also improve outcomes, including survival, in the appropriate clinical situations. LDTs, including hepatic artery infusion, radioembolization, radiation, and ablation techniques, such as thermal ablation and histotripsy, offer local control and potential systemic effects, including the abscopal effect. The abscopal effect occurs when nontargeted, nontreated tumors regress following localized therapy to other tumors. Preclinical and clinical studies suggest that antigen-induced upregulation of key immune regulators plays a central role in this process. Unfortunately, clinical reports of the abscopal effect following LDT are exceedingly rare. However, histotripsy, a noninvasive, nonionizing, and nonthermal ablation technique, may induce an abscopal effect more frequently and robustly than other LDTs. Histotripsy enhances tumor immunogenicity through precise acoustic cavitation that better preserves the local tissue architecture while increasing antigen release, resulting in a robust local and systemic immune response. Ongoing trials are investigating these immunogenic mechanisms and the ability to generate an abscopal effect more reliably with adjuncts such as checkpoint inhibitors. This work has significant implications regarding the management of patients with liver metastasis.


  • Deaf and Disabled Representation in the US Physician Workforce

    by Colin Hill, Michelle Ludwig, Lisa Meeks, Christopher Moreland, Philip Zazove

  • Open Access

    Inter-Breath-Hold Geometric and Dosimetric Variations in Organs at Risk during Pancreatic Stereotactic Body Radiotherapy: Implications for Adaptive Radiation Therapy

    by Hamed Hooshangnejad, Devin Miles, Colin Hill, Amol Narang, Kai Ding, Sarah Han-Oh

    Pancreatic cancer is the fourth leading cause of cancer-related death, with nearly 60,000 cases each year and less than a 10% 5-year overall survival rate. Radiation therapy (RT) is highly beneficial as a local-regional anticancer treatment. As anatomical variation is of great concern, motion management techniques, such as DIBH, are commonly used to minimize OARs toxicities; however, the variability between DIBHs has not been well studied. Here, we present an unprecedented systematic analysis of patients’ anatomical reproducibility over multiple DIBH motion-management technique uses for pancreatic cancer RT. We used data from 20 patients; four DIBH scans were available for each patient to design 80 SBRT plans. Our results demonstrated that (i) there is considerable variation in OAR geometry and dose between same-subject DIBH scans; (ii) the RT plan designed for one scan may not be directly applicable to another scan; (iii) the RT treatment designed using a DIBH simulation CT results in different dosimetry in the DIBH treatment delivery; and (iv) this confirms the importance of adaptive radiation therapy (ART), such as MR-Linacs, for pancreatic RT delivery. The ART treatment delivery technique can account for anatomical variation between referenced and scheduled plans, and thus avoid toxicities of OARs because of anatomical variations between DIBH patient setups.


  • Open Access

    The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer

    by Timothy Lin, Abhinav Reddy, Colin Hill, Shuchi Sehgal, Jin He, Lei Zheng, Joseph Herman, Jeffrey Meyer, Amol Narang

    We aimed to evaluate the impact of time from stereotactic body radiation therapy (SBRT) to surgery on treatment outcomes and post-operative complications in patients with borderline resectable or locally advanced pancreatic cancer (BRPC/LAPC). We conducted a single-institutional retrospective analysis of patients with BRPC/LAPC treated from 2016 to 2021 with neoadjuvant chemotherapy followed by SBRT and surgical resection. Covariates were stratified by time from SBRT to surgery. A Cox regression model was used to identify variables associated with survival outcomes. In 171 patients with BRPC/LAPC, the median time from SBRT to surgery was 6.4 (range: 2.7–25.3) weeks. Hence, patients were stratified by the timing of surgery: ≥6 and p = 0.042), pathologic node positivity, elevated baseline CA19-9, and inferior LC if of the male sex. In multivariable analysis, surgery ≥6 weeks (p = 0.013; HR 0.46, 95%CI 0.25–0.85), node positivity (p = 0.019; HR 2.09, 95% CI 1.13–3.88), and baseline elevated CA19-9 (p = 0.002; HR 2.73, 95% CI 1.44–5.18) remained independently associated with LC. Clavien–Dindo Grade ≥3B complications occurred in 4/63 (6.3%) vs. 5/99 (5.5%) patients undergoing surgery p = 0.7). In summary, the timing of surgery ≥6 weeks after SBRT was associated with improved local control and low post-operative complication rates, irrespective of the surgical timing. Further investigation of the influence of surgical timing following radiotherapy is warranted.


  • Open Access

    Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy

    by Abhinav V. Reddy, Colin S. Hill, Shuchi Sehgal, Lei Zheng, Jin He, Daniel A. Laheru, Ana De Jesus-Acosta, Joseph M. Herman, Jeffrey Meyer, Amol K. Narang

    Purpose: To investigate the role of pre- and post-stereotactic body radiation therapy (SBRT) neutrophil-to-lymphocyte ratio (NLR) in patients with localized pancreatic cancer treated with anti-PD-1 (programmed cell death protein-1) antibody and SBRT.Materials and Methods: This was a retrospective review of 68 patients with borderline resectable or locally advanced pancreatic cancer treated with anti-PD-1 antibody and SBRT after multi-agent chemotherapy. Immunotherapy was administered with 5-fraction SBRT in the neoadjuvant, concurrent, or adjuvant/maintenance setting. Clinical outcomes included overall survival (OS), local progression-free survival, distant metastasis-free survival, and progression-free survival. Median pre- and post-SBRT peripheral blood markers were compared with the Mann-Whitney U test. Univariate and multivariable analyses (UVA and MVA) were performed to identify variables associated with clinical outcomes. Linear regression was performed to determine correlations between variables and peripheral blood markers. Results: A total of 68 patients were included in the study. The percent change between median pre- and post-SBRT absolute lymphocyte count (ALC), absolute neutrophil count, and NLR were -36.0% (p < 0.001), -5.6% (p = 0.190), and +35.7% (p = 0.003), respectively. Median OS after SBRT was 22.4 months. On UVA, pre-SBRT CA19-9 (hazard ratio [HR] = 1.001; 95% confidence interval [CI], 1.000–1.001; p = 0.031), post-SBRT ALC (HR = 0.33; 95% CI, 0.11–0.91; p = 0.031), and post-SBRT NLR (HR = 1.13; 95% CI, 1.04–1.22; p = 0.009) were associated with OS. On MVA, induction chemotherapy duration (HR = 0.75; 95% CI, 0.57–0.99; p = 0.048) and post-SBRT NLR (HR = 1.14; 95% CI, 1.04–1.23; p = 0.002) predicted for OS. Patients with post-SBRT NLR ≥3.2 had a median OS of 15.6 months versus 27.6 months in patients with post-SBRT NLR <3.2 (p = 0.009). On MVA linear regression, log10CTV had a negative correlation with post-SBRT ALC (regression coefficient = -0.314; 95% CI, -0.626 to -0.003; p = 0.048). Conclusion: Elevated NLR after SBRT is primarily due to depletion of lymphocytes and associated with worse survival outcomes in localized pancreatic cancer treated with anti-PD-1 antibody. Larger CTVs were associated with decreased post-SBRT ALC.


  • Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial

    by Colin S. Hill, Lauren Rosati, Hao Wang, Hua-Ling Tsai, Jin He, Amy Hacker-Prietz, Daniel A. Laheru, Lei Zheng, Shuchi Sehgal, Vincent Bernard, et al.


  • Open Access

    High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy

    by Colin Hill, Shuchi Sehgal, Wei Fu, Chen Hu, Abhinav Reddy, Elizabeth Thompson, Amy Hacker‐Prietz, Dung Le, Ana De Jesus‐Acosta, Valerie Lee, et al.

    Background: Stereotactic body radiation therapy (SBRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma (BRPC/LAPC) remains controversial. Herein, we report on surgical, pathologic, and survival outcomes in BRPC/LAPC patients treated at a high‐volume institution with induction chemotherapy (CTX) followed by 5‐fraction SBRT.Methods: BRPC/LAPC patients treated between 2016 and 2019 were retrospectively reviewed. Surgical and pathological outcomes were descriptively characterized. Overall survival (OS) and progression‐free survival (PFS) were analyzed using Cox proportional hazard regression. Locoregional failure and distant failure were analyzed with Fine–Gray competing risk model.Results: Of 155 patients, 91 (59%) had LAPC and 64 (41%) had BRPC. Almost all were treated with induction multi‐agent CTX with either FOLFIRINOX (75%) or gemcitabine and nab‐paclitaxel (24%) for a median duration of 4.0 months (1–18 months). All received SBRT to a median dose of 33 Gy. Among 64 BRPC patients, 50 (78%) underwent resection, of whom 48 (96%) achieved margin‐negative (R0) resection. Among 91 LAPC patients, 57 (63%) underwent resection, of whom 50 (88%) achieved R0 resection. Despite the high R0 rate, 33% of patients experienced locoregional failure, which was a component of 44% of all failures. After SBRT, median OS and PFS were 18.7 and 7.7 months, respectively. After SBRT, 1‐ and 2‐year OS probabilities were 70% and 45%, whereas, from diagnosis, they were 93% and 51%.Conclusions: Although a high proportion of BRPC/LAPC patients treated with induction multi‐agent CTX followed by SBRT successfully achieved R0 resection, locoregional failure remained common, highlighting the need to continue to optimize radiation delivery in this context.